Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 6/20 | 0.64 |
| ▸ | CA1 | P00915 | 6/20 | 0.64 |
| ▸ | CA2 | P00918 | 6/20 | 0.64 |
| ▸ | CA7 | P43166 | 6/20 | 0.64 |
| ▸ | CA9 | Q16790 | 6/20 | 0.64 |
| ▸ | CA13 | Q8N1Q1 | 6/20 | 0.64 |
| ▸ | CA3 | P07451 | 3/20 | 0.64 |
| ▸ | CA4 | P22748 | 3/20 | 0.64 |
| ▸ | CA6 | P23280 | 3/20 | 0.64 |
| ▸ | CA5A | P35218 | 3/20 | 0.64 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.64 |
| ▸ | CA5B | Q9Y2D0 | 3/20 | 0.64 |
| ▸ | ALPL | P05186 | 2/20 | 0.56 |
| ▸ | ALPG | P10696 | 2/20 | 0.56 |
| ▸ | ALPI | P09923 | 1/20 | 0.56 |
| ▸ | PLAA | Q9Y263 | 1/20 | 0.56 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.56 |
| ▸ | NPC1 | O15118 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | PKM | P14618 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5094283 | 0.79 | GAA (0.70) | NPC1RAB9ASMN1; SMN2GLATHRB | |
| SCHEMBL18424833 | 0.78 | CA12 (1.00) | CA12CA1CA2CA7CA9 | |
| SCHEMBL5094279 | 0.76 | ALDH1A1 (0.54) | CA12CA1CA9P2RX7LMNA | |
| SCHEMBL18825270 | 0.76 | CA12 (0.71) | CA12CA1CA2CA7CA9 | |
| SCHEMBL20715687 | 0.75 | CYP11B1 (0.66) | NPC1LMNAPKMRAB9ASMN1; SMN2 | |
| SCHEMBL1035783 | 0.74 | EGLN3 (0.71) | CA12CA1CA2CA7CA9 | |
| SCHEMBL5334232 | 0.73 | ALPL (0.59) | CA12CA1CA2CA7CA9 | |
| SCHEMBL18425991 | 0.72 | CA1 (1.00) | CA12CA1CA2CA7CA9 | |
| SCHEMBL22381004 | 0.72 | CA1 (1.00) | CA12CA1CA2CA7CA9 | |
| SCHEMBL25516474 | 0.72 | CA12 (0.64) | CA12CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7425557-B2 | Inhibitors of glycogen synthase kinase 3 | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2008-09-16 | — | — | US | disclosed |
| US-7425557-B2 | Inhibitors of glycogen synthase kinase 3 | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2008-09-16 | — | — | US | disclosed |
| US-7045519-B2 | Inhibitors of glycogen synthase kinase 3 | CHIRON CORPORATION (US) | 2006-05-16 | — | — | US | disclosed |
| US-7037918-B2 | Inhibitors of glycogen synthase kinase 3 | CHIRON CORPORATION (US) | 2006-05-02 | — | — | US | disclosed |
| US-20060089369-A1 | Inhibitors of glycogen synthase kinase 3 | CHIRON CORPORATION (US) | 2006-04-27 | — | — | US | disclosed |
| US-20050272036-A1 | Ketones | ASTRAZENECA AB (SE) | 2005-12-08 | — | — | US | disclosed |
| EP-1549600-A1 | KETONES | AstraZeneca AB (SE) | 2005-07-06 | — | — | EP | disclosed |
| EP-1087963-B1 | INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 | CHIRON CORP (US) | 2004-08-25 | — | — | EP | disclosed |
| WO-2004011410-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2004-02-05 | — | — | WO | disclosed |
| US-20030130289-A1 | Inhibitors of glycogen synthase kinase 3 | CHIRON CORPORATION | 2003-07-10 | — | — | US | disclosed |
| EP-1317433-A2 | INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 | CHIRON CORPORATION (US) | 2003-06-11 | — | — | EP | disclosed |
| US-6489344-B1 | FOR TREATMENT DIABETES IN A HUMAN OR ANIMAL SUBJECT | CHIRON CORPORATION | 2002-12-03 | — | — | US | disclosed |
| US-20020156087-A1 | Inhibitors of glycogen synthase kinase 3 | CHIRON CORPORATION | 2002-10-24 | — | — | US | disclosed |
| WO-2002020495-A2 | INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 | CHIRON CORPORATION (US) | 2002-03-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130289-A1 | Inhibitors of glycogen synthase kinase 3 | GSK3B, GSK3A, PYGB | CA12 4344/4885CA1 2045/4885CA2 3046/4885 |
| US-20060089369-A1 | Inhibitors of glycogen synthase kinase 3 | GSK3B, GSK3A, PYGB | CA12 4374/4885CA1 2163/4885CA2 3079/4885 |
| US-20020156087-A1 | Inhibitors of glycogen synthase kinase 3 | GSK3B, GSK3A, PYGB | CA12 4374/4885CA1 2163/4885CA2 3079/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.